BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/30/2024 3:48:50 AM | Browse: 54 | Download: 206
 |
Received |
|
2024-07-15 14:27 |
|
Peer-Review Started |
|
2024-07-15 14:27 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-09-07 23:54 |
|
Revised |
|
2024-09-17 14:34 |
|
Second Decision |
|
2024-10-16 07:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-11-05 08:24 |
|
Articles in Press |
|
2024-11-05 08:24 |
|
Publication Fee Transferred |
|
2024-11-14 10:28 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-22 00:23 |
|
Publish the Manuscript Online |
|
2024-11-30 03:48 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Case Report |
| Article Title |
Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fang Chen, Bo An, Wen-Cheng An, Gang Fu, Wei Huang and Hui-Xian Yan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hui-Xian Yan, Associate Chief Physician, MD, PhD, Department of Endocrinology, Beijing Haidian Hospital, No. 29 Zhongguancun Street, Haidian District, Beijing 100080, China. yanhuixianhd@163.com |
| Key Words |
Dorzagliatin; Type 2 Diabetes Mellitus; Peritoneal Dialysis; Glucokinase activator; Glucose control; Case report |
| Core Tip |
Treating diabetes in dialysis patients remains a challenge, with many hypoglycemic drugs requiring dose adjustments or avoidance in these patients. To our knowledge, this report is the first to use Dorzagliatin in the treatment of type 2 diabetes peritoneal dialysis patients with challenging glucose control. Dorzagliatin, a novel glucokinase activator primarily metabolized by the liver, exhibits no pharmacokinetic differences among patients with varying degrees of chronic kidney disease, has a high plasma protein binding rate, and may not be cleared by peritoneal dialysis, potentially offering a new glycemic control option for Type 2 diabetic patients on peritoneal dialysis. |
| Publish Date |
2024-11-30 03:48 |
| Citation |
<p>Chen F, An B, An WC, Fu G, Huang W, Yan HX. Application of Dorzagliatin in peritoneal dialysis patients with type 2 diabetes mellitus: A case report. <i>World J Diabetes</i> 2025; 16(1): 99135</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v16/i1/99135.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v16.i1.99135 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
